Webinar

Bispecific T cell engager development represents an unique challenge for dose justification and safety, as high potency and risk of cytokine release often make traditional MABEL approaches overly conservative; in this webinar, we will walk through the essential building blocks of modern bispecific antibody mechanistic models and show how these components are implemented in published case studies and leveraged to support First-in-Human (FIH) dose selection.

This webinar will also serve as a gateway to our upcoming hands‑on workshop on Model‑informed approach for safe starting dose estimation in First‑in‑Human trials, which will be held as a satellite meeting at the PAGE 2026 conference in Dubrovnik, Croatia. There, we will expand on the same modeling concepts in an interactive format, working through real bispecific case study from data to decision and providing practical templates you can adapt to your own projects. To register for the workshop, please visit our registration page.